CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Short Interest Up 771.2% in September

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) saw a significant increase in short interest in September. As of September 30th, there was short interest totalling 2,320,000 shares, an increase of 771.2% from the September 15th total of 266,300 shares. Based on an average daily volume of 10,160,000 shares, the days-to-cover ratio is currently 0.2 days. Currently, 10.2% of the shares of the stock are sold short.

CERo Therapeutics Stock Performance

Shares of CERO stock remained flat at $0.10 during trading hours on Friday. 2,970,753 shares of the stock were exchanged, compared to its average volume of 4,615,295. CERo Therapeutics has a 12 month low of $0.07 and a 12 month high of $12.80. The business has a fifty day moving average price of $0.12 and a two-hundred day moving average price of $0.66.

CERo Therapeutics (NASDAQ:CERO) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.33) EPS for the quarter.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.